Consequently, excessive activation of TGF-β (derived from cancer cells and the tumour microenvironment) by plasmin would lead to increased PAI1 secretion and inhibition of fibrinolysis, thus permanently increasing the risk of thrombosis in cancer patients (Fig. 1B). The gene discussed is TGFB1; the disease is neoplasm.